Research into the molecular genetic causes of cancer was founded by analyses of avian retroviruses. Two genes which have ®gured prominently in this history are the Myc and Myb oncogenes, which were initially identi®ed as the cancer-causing principles of the avian retroviruses MC29 and AMV. Since their molecular cloning and the subsequent identi®cation of their cellular homologs almost two decades ago, both oncogenes have been intensely studied, with 410 000 publications on Myc and 41400 publications on Myb currently found in the biomedical research literature. Surprisingly, despite the huge eort implied by this literature, de®ning the roles of Myc and Myb in neoplastic transformation has continued to challenge and frustrate researchers. Myc in particular continues to be a siren because of its central role in a large fraction of human cancers, and its function and regulation remains to a surprising degree unresolved. Ironically, while Myc research has stimulated diverse hypotheses with wide applications in molecular and cellular biology, understanding has lagged about Myc itself. Recently, however, the veils shrouding Myc and Myb may at last be lifting. The reviews collected here parse recent advances, but the aim is not so much to comprehensively survey the literature as to provide viewpoints that synthesize new and old ®ndings, stimulate and extend hypotheses, reassess existing paradigms, and promote new insights.
Origins
Myc was identi®ed originally as the oncogene in the avian myelocytomatosis virus MC29 but has been identi®ed in several other retroviruses as well. The classic Myc-transformed cell is myeloid and welldierentiated. However, Myc transforms a variety of hematopoietic and nonhematopoietic cell types. Several nonredundant cellular homologs of v-Myc exist that are similar in structure to the viral oncoprotein (with point variations), with c-Myc being the most widely expressed. Myc appears to have arisen relatively late in evolution. A Myc-like gene has been found in star®sh, although it is unclear if this gene is functionally homologous. A bona®de Myc gene was ®nally identi®ed after a long search in Drosphila but there is no sign of Myc sequences in either yeast or C. elegans. Interestingly, the Myc partner protein Max and the Max-binding Mad proteins appear to have been identi®ed in C. elegans, suggesting the Myc/Max complex evolved later. Given its more recent evolution, Myc may have more complex or highly integrated functions than more ancient genes. Investigations of Myc have been slowed by the lack of a genetically malleable system that could help identify physiological functions. This situation is now remedied by the identi®cation of the Drosophila Myc homolog, which appears to be allelic to diminutive (mutation of which causes a cell growth de®cient phenotype).
Myb was identi®ed originally in avian myeloblastosis virus (AMV). The classic v-Myb-transformed cell is myeloid and has a relatively undierentiated character. In contrast to Myc, only hematopoietic cells are transformed by Myb, restricting its role in cancer. A second Myb-containing virus, E26, encodes a chimeric protein which includes sequences from Gag, Myb, and the transcription factor Ets and which causes erythroblastosis instead of leukemia. Several cellular Myb homologs exist which include N-and C-terminal extensions relative to v-Myb, including the tissue speci®c genes c-Myb and A-Myb and the ubiquitously expressed gene B-Myb. The C-terminal extension of cMyb which is deleted in v-Myb is a negative regulatory domain. Myb is conserved in evolution and Mybrelated genes have been found in yeast. Ongoing analysis of a Myb homolog in Drosophila suggests roles in cell cycle and promises to provide key insights into physiological functions.
State of the art
Myc and Myb are each strongly implicated in transcriptional regulation. Myc's role in transcription was cued in the late 1980s by the discovery of adjacent sequence motifs in its C-terminus for the`leucine zipper', the helix ± loop ± helix, and the basic region, which permitted workers to bootstrap to DNA recognition and transactivation functions. Myb has followed a similar course that was stimulated by the identi®cation of DNA binding sites. Regulation of Myc and Myb, at both the level of the gene and protein, has not delivered many deep insights but this situation is now changing. The most intense activity has been at the functional level, particularly in de®ning target genes which are activated or repressed in response to Myc and Myb expression. In the Myc ®eld, this interest has been driven by the anticipation that the regulation of dierent batteries of target genes will yield under-*Correspondence: GC Prendergast standing into the diverse biological eects of Myc which have been documented (i.e. cell cycle regulation, malignant transformation, apoptosis, translation/metabolism, embryonic development, and cell differentiation). Technical barriers are being broken that had impeded the identi®cation of proteins that interact with the N-terminus of Myc, which includes its transcriptional regulatory domain, and in the analysis of in vivo DNA binding properties of Myc-containing complexes. Advances on these fronts is extending and challenging the existing paradigms of how Myc may cause malignant transformation. In the Myb ®eld, the identi®cation of target genes and binding proteins has also been an area of major interest, with advances being made concerning the casual connection between Myb and human leukemia and the relationship of Myb to other growth regulatory systems in the cell. Interestingly, recent work suggests the existence of cooperative links between Myc and Myb in lymphomagenesis. For both oncoproteins, connections to cell cycle, apoptosis, and transcriptional machinery are emerging and opening new realms for hypothesis and experimentation.
Future issues
It is clear the Myc and Myb each manifest their biological properties by associating with speci®c sites in chromatin. However, exactly what physiological loci they bind and what they do once bound is much less clear, especially in the case of Myc. Recent investigations of Myb strongly support a role as a classical activator and/or repressor of transcription whose action may be coordinated by cell cycle signals. One would hope that the exact relationship between Myb and human malignancy can be pinned down and that mechanistic insights may yield possible therapeutic approaches. With Myc, its exact roles in transcription may ®nally begin to be established, given that old problems are beginning to be overcome (e.g. biochemical diculties in handling native Myc; the paucity of interacting factors and physiological target genes with which to probe various biological functions; and the inability to monitor the activity of in vivo Myc DNA binding complexes). The existing cadre of adaptor proteins that interact with the transactivation domain of Myc suggest cell cycle and signaling functions, but do not yet include any obvious coactivators or corepressors. This situation promises to change rapidly as adaptor-binding proteins are de®ned and functionally analysed. It is also exciting to anticipate the prospects of understanding the greater complexities of Myc, long hinted at, which extend beyond the functions of`classic' transcription factors. In the near future Myc and Myb may ®nally yield long sought knowledge into how they aect normal and neoplastic cell regulation, but in any case they will certainly continue to oer realms for building productive and valuable hypotheses.
